Clinical Trials Browser

OTHER × Triple Negative Breast Neoplasms × Colony-Stimulating Factors × Clear all

Triple Negative Breast Neoplasms

NCT07078604 2026-04-07

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Phase 2 Recruiting

20 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

132 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03012100 2023-01-13

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

Phase 2 Active not recruiting

280 enrolled

Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

PNeoVCA

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer